Markets News
Latest stock market news and real-time market analysis. Track S&P 500, Nasdaq, and Dow Jones movements, sector rotations, and breaking market events.
Nu Holdings Heavy Volume Signals Caution Amid Mexico Bank Approval
Nu Holdings (NU) saw 133 million shares trade Monday, 239% of average, but stock closed flat at $13.67. Mexico bank approval and new CFO mark execution milestones, not price catalysts.
Lloyds Buyback Loses Punch as Share Rally Cuts Purchasing Power
Lloyds' share rally has reduced the effectiveness of its £1.75 billion buyback, with each pound now buying fewer shares despite a larger budget.
Oil Majors BP and Shell Cushion FTSE 100 Decline Amid Broader Sell-Off
BP and Shell gains masked a sharper FTSE 100 decline on Tuesday, as oil prices rose on US-Iran tensions. The FTSE 250 fell 0.76%, reflecting broader market weakness.
National Grid Bounces Back 84% from AI Deal Dip as £70 Billion Spending Plan Looms
National Grid shares have recovered 84% of the post-Joulent drop ahead of its AGM, where a £70 billion borrowing limit will be adopted. The company's record capex plan and rising debt are in focus.
Shell Outpaces FTSE as Asset Sales and Oil Rally Reshape ARC Deal
Shell shares rose 1.7% on Tuesday after the company agreed to sell its Indian renewables business, adding to a $5.8 billion disposal program that helps fund its acquisition of ARC Resources.
Standard Chartered Shares Slip on Wealth Management Deal; Analyst Targets Capped
Standard Chartered shares dipped 0.9% on a new wealth management partnership with BlackRock, as analyst targets imply only 4.8% upside before half-year results.
HSBC Shares Slip 9% from High, Analyst Targets Show Limited Upside
HSBC shares fell 0.8% to 1,450.2p, now 8.8% below their July 6 high. The median 12-month analyst target of 1,471.77p offers just 1.5% upside, leaving little room for error ahead of interim results on Aug 4.
Agenus Shares Surge 83% on $340M Financing for Key Colon Cancer Trial
Agenus shares surged 83% on news of up to $340M financing for a pivotal colon cancer trial, but three-quarters of that amount hinges on investor warrants.
